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ABSTRACT 1 
Purpose 2 
To report the 12-month outcomes of 1,140 treatment-naïve eyes with exudative age-related 3 
macular degeneration (wet AMD) who were treated for 12 months with intravitreal anti-4 
VEGF drugs in routine clinical practice.  5 
Methods 6 
Index visit characteristics, such as lesion type and size, visual acuity (VA in logMAR 7 
[Logarithm of the Minimal Angle of Resolution] letters), as well as treatments, outcomes 8 
(VA, lesion activity status) and ocular adverse events were recorded in a prospectively 9 
designed electronic database. Index visit characteristics associated with the 12-month VA 10 
outcome were identified using mixed effects linear regression. 11 
Results 12 
Mean change in VA in the cohort after 12 months was +4.7 logMAR letters (95%CI: 3.4 to 13 
6.1) with a mean of 7.0 injections. No significant difference was found in change in VA or 14 
number of injections by type or size of the lesion. Median time to inactivation of lesions was 15 
194 days. VA at the index visit was the strongest predictor for the 12-month outcomes. 16 
Infectious endophthalmitis occurred in 2 cases, retinal detachment in 1 case from a total of 17 
9,162 injections. 18 
Conclusion 19 
These findings indicate that VEGF inhibitors can achieve reasonably good outcomes for wet 20 
AMD when used in routine clinical practice.  21 
 22 
  23 
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While the efficacy of ranibizumab (Lucentis ®, Novartis, Switzerland), bevacizumab 1 
(Avastin ®, Roche, Switzerland) and aflibercept (Eylea®, Bayer, Switzerland) for exudative 2 
age-related macular degeneration (wet AMD)1 has been convincingly demonstrated by tightly 3 
controlled phase 3 clinical trials,2-7 it is still not certain that the results of these studies will be 4 
replicated in the real world after the new drugs have been approved for general use. Many 5 
patients being treated for wet AMD in the general community may not have met inclusion 6 
criteria of the clinical trials. Even if they had, a heavy treatment burden on all involved in 7 
routine retinal practice has led to dosing regimens that are less intensive than those used in 8 
the pivotal trials, such as the pro re nata (PRN) and treat-and-extend regimens.8,9 9 
 10 
The Fight Retinal Blindness! (FRB) Project has established a prospective audit system that 11 
can anonymously track outcomes of treatment of retinal disease, such as wet AMD, in large 12 
numbers of patients treated in routine retinal treatment centres.10 Here we describe the 12-13 
month outcomes, including visual acuity, grading of lesion activity and adverse events, for 14 
1,140 treatment-naive participants in the FRB! Project wet AMD audit.   15 
5 
 
METHODS 1 
Study design & Setting 2 
This is an observational study utilising anonymised longitudinal data from the FRB registry 3 
that were captured during routine clinical practice. All treatment decisions and visit schedules 4 
were entirely at the discretion of the treating physician and patient. Details of the FRB project 5 
data tracking system have been published.10 The research followed the tenets of the 6 
declaration of Helsinki. Patients were given information regarding the project and given the 7 
opportunity to opt out of the project. Each of the three academic core centres from the 8 
Universities of Sydney, Melbourne and Western Australia obtained approval from their 9 
respective Human Research Ethics Committees (HREC) to conduct the project as a quality 10 
assurance activity. Overarching ethical approval for the other centres was obtained from the 11 
Royal Australian and New Zealand College of Ophthalmologists’ HREC. 12 
Patient data recorded from 27 retinal specialists located across Australia from January 2006 13 
until September 2012 were aggregated for analysis. The project began collecting data from 14 
the core centres in Sydney, Melbourne and Perth then spread to non-academic retinal services 15 
in the capital cities of most Australian states.  16 
 17 
Participants and Variables 18 
Few eligibility criteria were applied beyond treatment-naïve eyes commencing treatment for 19 
wet AMD that had been diagnosed by their treating ophthalmologist with VA > 20 letters. All 20 
eyes in the database that commenced treatment between Jan 2004 and Nov 2011 were 21 
included in this analysis, so that all potentially had 12 months follow-up. At the index visit, 22 
i.e. the visit at which treatment was commenced, the study participants’ age, angiographic 23 
lesion criteria such as lesion type and greatest linear dimension (GLD), visual acuity 24 
(Logarithm of the Minimum Angle of Resolution – LogMAR, recorded as letters read), 25 
choroidal neovascularization (CNV) status (active, inactive), along with treatment history and 26 
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treatment decisions (treated or not treated and name of drug used) were recorded. 1 
Investigators were asked to enter whichever VA reading was best: uncorrected, corrected or 2 
pinhole. The best VA achieved during each visit was used for analysis. The judgement of 3 
“active” or “inactive” was left to the investigator’s discretion, thus reflecting real-world 4 
practice. It was suggested that Users should grade lesions as active if there was intra- or sub-5 
retinal fluid, or any other feature, present that could be attributed to activity of the 6 
neovascular lesion. Follow-up visits recorded subsequent VA, CNV status, all treatment 7 
decisions and any ocular adverse events. Three subgroups of interest were pre-specified: 8 
occult lesions (OC), minimally classic lesions (MC) and predominantly classic lesions (PC). 9 
 10 
Statistical methods 11 
For continuous variables means or medians and interquartile range (Q1, Q3) were computed. 12 
Seventeen percent of patients contributed both eyes to the study database; when measuring 13 
variation and performing statistical tests at the index visit, fellow eyes were randomly 14 
removed to ensure any possible inter-eye correlation would not bias estimates. Formal 15 
comparisons were made using the non-parametric Kolmogorov-Smirnoff (KS) test, which is 16 
sensitive to any difference in the underlying distribution of two samples. 17 
 18 
The outcomes analysis used data from all eyes that completed 12 months follow-up, while the 19 
safety analysis set included all available data over 12 months. We also examined outcomes 20 
for eyes that did not complete 12 months follow-up due to withdrawal from treatment or loss 21 
to follow-up. Study endpoints included 12-month longitudinal VA, time from first intravitreal 22 
injection to inactivation of CNV and change in CNV status over 12 months. Within-eye 23 
changes in VA over 12 months were tested using the paired t-test. Longitudinal VA data were 24 
plotted using a Lowess smoothed regression line.11,12 A mixed effects regression model was 25 
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fitted to the longitudinal VA data to examine the effects of lesion type, GLD and age on VA 1 
at 12 months. 2 
 3 
Kaplan-Meier analysis13 was used to examine time from first injection to inactivation of CNV 4 
status. All observed adverse events were tabulated and reported. Analysis and plots were 5 
done using R version 2.15.0.14 6 
 7 
 8 
9 
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RESULTS 1 
There were 1,140 eyes that completed 12 months follow-up (10,758 visits). The study 2 
population was 61% female and the mean age was 79.3 years (Q1,Q3: 75, 85). Mean visual 3 
acuity at the index visit was 57.1 letters (Q1,Q3: 45, 69) (Table 1). Owing to the quality 4 
assurance features of the FRB web-based data entry system, data quality was high for all 5 
variables (> 99.5% complete) with the exception of GLD (80% complete) and lesion type 6 
(88% complete).  7 
 8 
Table 1: Index visit characteristics of eyes that completed 12 months follow-up and those that 9 
did not 10 
Characteristic 12-month Completers Non-completers 
Eyes 1,140 230 
Visits 10,758 1,496 
Median days follow-up (Q1, 
Q3) 
- 210 (111, 302) 
Mean index VA (Q1, Q3) 57.1 (45, 69) 52.5 (40, 65) 
Mean age (Q1, Q3)  79.3 (75, 85) 79.9 (75, 85) 
Female 61.3% 58.3% 
Median GLD (Q1, Q3)  2,000 (1,300, 3,050) 2,315 (1,500, 3,390) 
Lesion type 
 
     Occult n (%) 529 (53.6 %) 109 (51.4 %) 
     Minimally classic n (%) 211 (21.4 %) 50 (23.6 %) 
     Predominantly classic n (%) 171 (17.3 %) 43 (20.3 %) 
     Other n (%) 76 (7.7 %) 10 (4.7 %) 
     Unclassified n 163 18 
GLD: Greatest Linear Dimension; VA: LogMAR Visual Acuity 11 
 12 
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Treatment administered 1 
A total of 8,013 injections were given to the 1,140 eyes that completed 12 months, a mean 2 
(Q1,Q3) of 7.0 (5, 9) injections per eye (Table 2). The mean number of injections by lesion 3 
type was similar. The majority of injections administered were ranibizumab (91%) 4 
irrespective of lesion type, with the remainder being bevacizumab. For all lesion types the 5 
interval between injections was greater when lesions were graded as inactive than when they 6 
were graded as active. 7 
 8 
Table 2: Injection frequency and type over 12 months follow-up 9 
Occult Min class Pred class All
Mean (Q1, Q3) number of 
injections 
 
7.0 (5, 9) 6.8  (5, 9) 7.1 (5, 9) 7.0 (5, 9)
Median (Q1, Q3) days 
between injections when 
active  
 
35 (28, 52) 41 (29, 55) 35 (28, 56) 36 (28, 56)
Median (Q1, Q3) days 
between injections when 
inactive 
  
43 (35, 63) 49 (36, 63) 42 (33, 56) 42 (35, 63)
% Ranibizumab injections 91.3% 92.3% 91.4% 91.4%
Nin Class = minimally classic; predom = predominantly 10 
VA and GLD at the index visit 11 
There were notable differences in the distributions of VA and GLD among the lesion type 12 
subgroups (Table 3, Figure 1). Visual acuity when starting treatment was lower for the PC 13 
classic group than the OC subgroup (P<0.0001; KS-test) and the MC subgroup (P=0.01; KS-14 
10 
 
test). GLD was lower in the PC group than either OC or MC: OC vs. PC (P=0.002); MC vs. 1 
PC (P=0.005); OC vs. MC (P=0.5), (Figure 1).  2 
 3 
Table 3: Index visit visual acuity and greatest linear dimension with visual acuity change 4 
after 12 months 5 
    Occult Min class Pred class All 
Mean (Q1, Q3) VA Index visit  58.9 (50, 70) 57.1 (44, 67) 51.8 (37, 64) 57.1 (45, 69) 
Mean 12 month VA change  
(95%  CI*) 4.9 (2.1 to 7.1) 4.5 (1.9 to 7.1) 5.1 (1.9 to 8.2) 4.7 (3.4 to 6.1) 
Median (Q1, Q3) Index GLD  2,080 (1,255, 3,200) 2,015 (1,525, 3,030) 1,740 (1,065, 2,555) 2,000 (1,300, 3,050) 
* Bias corrected and accelerated bootstrap 95 % confidence intervals15 6 
 7 
Unadjusted 12 month VA outcomes 8 
The mean within-eye change in visual acuity was a +4.7 letter improvement (95%CI: 3.4 to 9 
6.1) for the study population as a whole. Similar clinically relevant mean improvements were 10 
observed for all subgroups (Figure 2A): OC +4.9 letters (95%CI: 2.1 to 7.1), MC +4.5 letters 11 
(95%CI: 1.9 to 7.1) and PC +5.1 letters (95%CI: 1.9 to 8.2). The Lowess lines indicate that 12 
all three groups exhibited a monotonic improvement throughout 12 months (Figure 2B).  13 
 14 
Modelled 12 month VA outcomes 15 
Given the observed imbalance at the index visit in VA and GLD for the 3 subgroups, a mixed 16 
effects regression model was fitted to the longitudinal VA measurements to mitigate potential 17 
confounding influences (Table 4). The model coefficients for the MC and PC lesions (relative 18 
to OC) of -1.3 and -0.5 respectively indicate that lesion subgroup had very little effect (less 19 
than 1.5 LogMAR letters) on visual acuity outcomes. The coefficient for Age of -0.03 20 
indicated slightly worse outcomes with increasing age: a three decade increase in age was 21 
associated with a decreased gain of 1 LogMAR letter after 12 months of treatment. A 1mm 22 
11 
 
(1,000 µm) increase in GLD was associated with a reduced gain of 0.5 letters. The coefficient 1 
for Time indicated an annual mean improvement of 3.1 letters. Visual acuity at the index visit 2 
was a highly significant predictor of outcome.  3 
 4 
Table 4: Coefficients from mixed effects model fit to 12-month longitudinal VA data. 5 
Model coefficient t value 
Index Visual Acuity 0.9 62.93
Index Visit Age -0.03 -1.00
MC (relative to OC) -1.3 -2.72
PC (relative to OC) -0.5 -0.98
GLD 1000μm -0.5 -2.95
1 Year Follow-up 3.1 6.50
 6 
Lesion activity over 12 months 7 
The median time from first intravitreal injection to lesions being graded as “inactive” was 8 
194 days (95%CI: 174 to 216, Figure 3). Thirty seven percent of eyes were persistently 9 
graded as active during the 12 months of treatment. The median time between injections was 10 
36 days (Q1,Q3: 28, 56) while the lesions were graded as “active” and 42 days (Q1,Q3: 35, 63) 11 
while graded “inactive”.  12 
 13 
Eyes that did not complete 12 months follow-up 14 
Two hundred and thirty eyes (17%) either withdrew from treatment or were lost to follow-up 15 
over the observed 12-month interval (non-completers). Median follow-up time for these eyes 16 
was 210 days (Q1,Q3: 111, 302). At the index visit non-completers were similar to completers 17 
in most respects except for lower VA (mean 57.1 vs. 52.5; P=0.0004, KS-test). The outcomes 18 
for non-completers are shown in longitudinal profiles in Fig 4.  19 
12 
 
 1 
Safety 2 
Ocular adverse events observed over 12 months follow-up are summarised in Table 5. The 3 
most common adverse event was patient-reported post-injection pain (45 instances). Two 4 
instances of infectious endophthalmitis were reported out of a total of 9,162 injections.  5 
 6 
Table 5: Adverse Events 7 
Frequency Injections per AE 
Post injection pain reported 45 204 
Haemorrhage reducing VA > 15 5 - 
Retinal detachment 1 9162 
Non-infectious endophthalmitis 2 4581 
Infectious endophthalmitis 2 4581 
RPE tear 12 764 
Cataract extraction / other surgery 15 611 
VA = Visual Acuity; RPE = Retinal Pigment Epithelium 8 
  9 
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DISCUSSION 1 
This analysis of outcome data that were collected prospectively and continuously from 2 
patients receiving treatment for exudative AMD has produced a number of observations on 3 
the use and outcomes of intravitreal therapy in routine practice. Mean visual acuity of the 4 
main cohort improved significantly by +4.7 logMAR letters over the first 12 months of 5 
treatment with a mean of 7 injections. The mean visual acuity of predominantly classic 6 
lesions improved slightly more than that of the minimally classic or occult groups, although 7 
eyes with predominantly classic lesions had lower visual acuity at the index visit. Otherwise, 8 
lesion type and size made little difference to the pattern of treatment outcomes, of which the 9 
strongest predictor was visual acuity at the first treatment visit. The median time to first 10 
grading of lesions as inactive was 194 days, with 37% still active at 12 months.  Safety 11 
findings were similar to previous reports. These findings indicate that VEGF inhibitors 12 
achieve good outcomes for wet AMD when used in routine clinical practice. 13 
 14 
Several other observational studies of intravitreal therapy for neovascular AMD have recently 15 
been published. The Swedish Lucentis Quality Registry found a good improvement in visual 16 
acuity after 3 injections of ranibizumab, but this subsequently dropped back to pre-treatment 17 
levels.16 Patients in that study received a mean of only 4.8 injections over 12 months, fewer 18 
than in the present study. Similar results were found by the WAVE study and an analysis of 19 
the German reinjection scheme.17,18 These studies that recorded lower gains in mean visual 20 
acuities also had a lower mean number of injections.  21 
 22 
An improvement in mean visual acuity after the first 12 months of treatment that was more 23 
similar to our results has been reported by two other observational studies. A gain of 3.2 24 
LogMAR letters was found with a mean of 5.1 injections in the French Lumiere study of 551 25 
patients.19 Menghini et al. reported a mean improvement of 5 letters with a mean of 4 26 
14 
 
injections in 204 eyes.20  1 
 2 
An overall mean improvement of 4.7 logMAR letters in the current report is still somewhat 3 
less than was reported in phase 3 clinical trials of ranibizumab.2,3 However the improvements 4 
in these studies were primarily measured against the change of vision in the control groups. 5 
Verteporfin-treated eyes had lost a mean of 9.5 letters by 12 months in ANCHOR, while 6 
sham-treated eyes had lost 10.4 letters in MARINA. Seen in this light, the increase in visual 7 
acuity found in the present analysis of outcomes of treated eyes in routine practice is 8 
reassuring. This was achieved with a mean of 7.0 injections, significantly more than was 9 
given in previously reported observational studies,16-20 out of potentially 13 that would be 10 
given with a strict monthly regimen. This frequency is similar to that of the CATT study, in 11 
which a mean of 6.9 injections were given to the ranibizumab PRN group and 7.7 to the 12 
bevacizumab PRN group.5  13 
 14 
Median time to grading the lesion as “inactive” was 194 days. Thirty seven percent of lesions 15 
were consistently graded as active throughout the first year of the study. As might be 16 
expected, these eyes received more injections. A related variable, presence of fluid at the 1-17 
year visit, was reported in 81% of bevacizumab PRN and 56% of ranibizumab monthly 18 
groups of the CATT study.5 It appears that reasonably good visual acuity outcomes can be 19 
obtained despite many eyes remaining active much or all of the time.  20 
 21 
Lesion characteristics, particularly lesion size (GLD) and type, did not significantly affect the 22 
outcomes of this study. Lesion type also had little effect on outcomes in retrospective 23 
analyses of MARINA and ANCHOR, in which mixed lesions had similar outcomes to purely 24 
classic or purely occult lesions.21,22 Menghini et al. also found no effect of lesion type on 25 
visual outcome after 24 months treatment in another observational study.20  In a recent report 26 
15 
 
from Comparison of AMD Treatment Trials, predominantly or minimally classic vs. occult 1 
CNV was not included in the final multivariate model of change in VA at 1 year because it 2 
was not statistically significant.23 Predominantly or minimally classic lesions 3 
were independently associated with less improvement in VA at 1 year in that study. Similarly, 4 
another recent report found no difference in VA outcome for occult, minimally classic or 5 
predominantly classic lesions in the PIER study.24  6 
 7 
The rate of serious adverse events was consistent with previous experience. Infectious 8 
endophthalmitis occurred in 2 patients, an incidence of 2.2 per 10,000 injections. Non-9 
infectious endophthalmitis was reported in 2 more cases. Retinal detachment occurred in 1 10 
eye, an incidence of 1.1 per 10,000 injections; this is similar to the rate at which retinal 11 
detachments are reported to occur in the general population.25 Mild adverse events appear to 12 
be under-reported, since there were only 45 episodes of post-injection pain. This indicates 13 
that registries may not accurately track outcomes that clinicians do not believe are clinically 14 
significant. 15 
 16 
This study, like all observational studies, has some limitations arising from the way in which 17 
data were collected. Subjective criteria such as lesion activity or lesion type may not be 18 
uniformly graded in observational studies since they are reported by the treating physicians 19 
rather than a centralised Reading Centre. Thus these determinations may have lower internal 20 
validity than in a phase 3 clinical trial, but perhaps they are still meaningful since this is how 21 
these clinically important determinations are actually being made in the real world. The 22 
measurement of LogMAR visual acuity, the main outcome, is reasonably objective. Also, 23 
case selection and treatment regimens in observational studies may be very different to 24 
clinical trials and among different ophthalmologists. Nevertheless, the data presented show 25 
16 
 
generally consistent outcomes of treatment regimens, which appeared to be similar across the 1 
different centres (data not shown).  2 
 3 
There are a number of further analyses that can be performed on observational data that we 4 
present here. A study of the efficacy of different treatment intensities will need to take into 5 
account “treatment by time” interactions (a treatment in the first 3 months is likely to have a 6 
greater affect than a treatment in the last 3 months) and the possibility that the outcome of 7 
treatment drives treatment intensity, with eyes responding poorly receiving more treatments 8 
than these that respond well, rather than vice versa. A study of poor responders would need to 9 
include not just the proportion of patients who, for example, lose 15 letters, but also analysis 10 
of their baseline characteristics, how the loss evolved over time and whether the causes could 11 
be identified by a case by case analysis referring back to the clinic notes in a selected 12 
subgroup. Treatment patterns and their different efficacies can also be identified: a pro re 13 
nata regimen will be revealed when treatments are given only when the lesion is graded as 14 
active, while a treat and extend regiment will have most treatments given when the lesion is 15 
graded as inactive. 16 
 17 
The significance of data from observational studies is that they provide an indication of what 18 
is happening in routine clinical practice, in contrast to results of phase 3 clinical trials, which 19 
may or may not be achievable in general. The results we present of intravitreal therapy for 20 
wet AMD are reasonably good, at least in the Australian centres that chose to participate. 21 
Further research is warranted to determine the functional implications of persistent activity 22 
and whether cohorts of patients receiving routine treatment do as well as those in phase 3 23 
studies when they are more closely matched to participants in those studies.  24 
  25 
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